Subcutaneous palivizumab (Synagis®) administration in an infant with congenital type 2B von Willebrand disease

Karel Allegaert, Maissa Rayyan, Veerle Cossey, Chris Van Geet


Intramuscular injections are contra-indicated in infants with either acquired or congenital bleeding disorders. In such patients, it is unlicensed practice to administer vaccines by subcutaneous route. However, there are no reports on subcutaneous administration of palivizumab (Synagis®). We report on the tolerance and effects of subcutaneous palivizumab administration in a former preterm girl with type 2B von Willebrand disease. Repeated subcutaneous injections of palivizumab were well tolerated with minor local reactions and no systemic side effects.
Consequently, we suggest to consider the subcutaneous instead of the intramuscular route in a setting of a valid indication for palivizumab, but a contraindication for intramuscular administration. More importantly, off-label or unlicensed practices should be reported to share and improve pharmacotherapy or at least illustrate knowledge gaps.


palivizumab, pharmacovigilance, subcutaneous, unlicensed practice, type 2B von Willebrand disease

Full Text: PDF Number of abstract views: 5179 Number of PDF views/downloads: 4723


N.B. All JPNIM articles are accessible in Open Access. You can access the page containing the full PDF article just by clicking on the “Full Text: PDF” link at the bottom of the abstract page. On the full article page, if the article doesn’t load properly in the PDF view window, please wait a few seconds or click on the “Download this PDF file” link.

Technical advice. If you are using Firefox and you are experiencing problems, please set the browser preferences as follows: Firefox > Preferences > Advanced > General > Accessibility > deselect "Warn me when web sites try to redirect or reload the page".

Privacy Policy. English text: Privacy Policy; Italian text: Privacy Policy.

Cookie Policy. English text: Cookie Policy; Italian text: Cookie Policy.